{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:30:27Z","timestamp":1740148227474,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T00:00:00Z","timestamp":1549670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T00:00:00Z","timestamp":1549670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2019,8,12]]},"DOI":"10.1007\/s12094-018-02032-4","type":"journal-article","created":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T09:21:31Z","timestamp":1549704091000},"page":"1093-1103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed\/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study"],"prefix":"10.1007","volume":"21","author":[{"given":"A.","family":"Amraee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Evazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Shakeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Roozbeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ghazanfarpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ghorbani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4757-2260","authenticated-orcid":false,"given":"L.","family":"Darvish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,9]]},"reference":[{"issue":"2","key":"2032_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s12185-016-2007-1","volume":"104","author":"S Makita","year":"2016","unstructured":"Makita S, Maruyama D, Maeshima AM, et al. Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. Int J Hematol. 2016;104(2):233\u201344.","journal-title":"Int J Hematol"},{"issue":"5","key":"2032_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s12185-010-0712-8","volume":"92","author":"M Ogura","year":"2010","unstructured":"Ogura M, Itoh K, Kinoshita T, et al. Phase II study of ABVd therapy for newly diagnosed clinical stage II\u2013IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305). Int J Hematol. 2010;92(5):713\u201324.","journal-title":"Int J Hematol"},{"key":"2032_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"2032_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","volume":"37","author":"J Weber","year":"2010","unstructured":"Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer\u2014preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010;37(5):430\u20139.","journal-title":"Semin Oncol"},{"issue":"26","key":"2032_CR5","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 anti-body in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"26","key":"2032_CR6","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"2","key":"2032_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/1078-0432.CCR-12-2625","volume":"19","author":"EJ Lipson","year":"2013","unstructured":"Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013;19(2):462\u20138.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2032_CR8","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein AP, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064\u201374.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"2032_CR9","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","volume":"17","author":"DJ Andorsky","year":"2011","unstructured":"Andorsky DJ, Yamada RE, Said J, et al. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17(13):4232\u201344.","journal-title":"Clin Cancer Res"},{"issue":"33","key":"2032_CR10","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","volume":"31","author":"P Armand","year":"2013","unstructured":"Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31(33):4199\u2013206.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2032_CR11","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","volume":"14","author":"R Berger","year":"2008","unstructured":"Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10):3044\u201351.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2032_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","volume":"15","author":"JR Westin","year":"2014","unstructured":"Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014;15(1):69\u201377.","journal-title":"Lancet Oncol."},{"issue":"10","key":"2032_CR13","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","volume":"114","author":"RA Wilcox","year":"2009","unstructured":"Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009;114(10):2149\u201358.","journal-title":"Blood"},{"issue":"9","key":"2032_CR14","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","volume":"107","author":"ZZ Yang","year":"2006","unstructured":"Yang ZZ, Novak AJ, Stenson MJ, et al. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood. 2006;107(9):3639\u201346.","journal-title":"Blood"},{"key":"2032_CR15","unstructured":"Keytruda (pembrolizumab). White-house Station, NJ: Merck (package insert). http:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf."},{"issue":"17","key":"2032_CR16","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268\u201377.","journal-title":"Blood."},{"issue":"32","key":"2032_CR17","doi-asserted-by":"publisher","first-page":"13134","DOI":"10.1073\/pnas.0706017104","volume":"104","author":"P Juszczynski","year":"2007","unstructured":"Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of galectin-1 by Reed\u2013Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA. 2007;104(32):13134\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7338","key":"2032_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nature09754","volume":"471","author":"C Steidl","year":"2011","unstructured":"Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471(7338):377\u201381.","journal-title":"Nature"},{"issue":"6","key":"2032_CR19","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","volume":"18","author":"MR Green","year":"2012","unstructured":"Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and post transplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18(6):1611\u20138.","journal-title":"Clin Cancer Res"},{"key":"2032_CR20","first-page":"2620","volume-title":"Clinical oncology","author":"D Kaufman","year":"2000","unstructured":"Kaufman D, Longo L. Hodgkin\u2019s disease. In: Lenhord ER, Osteen R, Gansler T, editors. Clinical oncology. 2nd ed. Livingstone: Churchill; 2000. p. 2620\u201348.","edition":"2"},{"key":"2032_CR21","first-page":"1215","volume-title":"Williams hematolog","author":"S Horning","year":"2001","unstructured":"Horning S. Hodgkin lymphoma. In: Beutler E, Lichtman M, Coller R, Kipps T, Seligsohn U, editors. Williams hematolog. 6th ed. New York: McGraw-Hill; 2001. p. 1215\u201328.","edition":"6"},{"issue":"1","key":"2032_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hon.683","volume":"20","author":"HC Fung","year":"2002","unstructured":"Fung HC, Nademanee AP. Approach to Hodgkin\u2019s lymphoma in the new millennium. Hematol Oncol. 2002;20(1):1\u201315.","journal-title":"Hematol Oncol"},{"key":"2032_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:311\u20139.","journal-title":"N Engl J Med"},{"issue":"26","key":"2032_CR24","first-page":"9","volume":"19","author":"F Abdi","year":"2016","unstructured":"Abdi F, Roozbeh N. The effects of Humulus lupulus L.) hops) on menopausal vasomotor symptoms: a systematic review and meta-analysis. Iran J Obstetrics Gynecol Infer. 2016;19(26):9\u201317.","journal-title":"Iran J Obstetrics Gynecol Infer."},{"issue":"5","key":"2032_CR25","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/cas.13230","volume":"108","author":"D Maruyama","year":"2017","unstructured":"Maruyama D, Hatake K, Kinoshita T, et al. Multicenter\u00a0phase II study\u00a0of\u00a0nivolumab\u00a0in\u00a0Japanese\u00a0patients\u00a0with\u00a0relapsed\u00a0or\u00a0refractory\u00a0classical Hodgkin lymphoma. Cancer Sci. 2017;108(5):1007\u201312.","journal-title":"Cancer Sci"},{"issue":"9","key":"2032_CR26","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, et al. Nivolumab\u00a0for\u00a0classical\u00a0Hodgkin\u2019s\u00a0lymphoma\u00a0after\u00a0failure\u00a0of both\u00a0autologous\u00a0stem-cell transplantation\u00a0and\u00a0brentuximab\u00a0vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283\u201394.","journal-title":"Lancet Oncol."},{"issue":"10","key":"2032_CR27","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1093\/annonc\/mdx341","volume":"28","author":"H Bek\u00f6z","year":"2017","unstructured":"Bek\u00f6z H, Karadurmus N, Paydas S, et al. Nivolumab\u00a0for\u00a0relapsed\u00a0or\u00a0refractory\u00a0Hodgkin lymphoma:\u00a0real-life\u00a0experience. Ann Oncol. 2017;28(10):2496\u2013502.","journal-title":"Ann Oncol"},{"issue":"5","key":"2032_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","volume":"22","author":"YL Kasamon","year":"2017","unstructured":"Kasamon YL, de Claro RA, Wang Y, et al. FDA\u00a0approval\u00a0summary:\u00a0nivolumab\u00a0for the\u00a0treatment\u00a0of\u00a0relapsed\u00a0or\u00a0progressive\u00a0classical hodgkin lymphoma. Oncologist. 2017;22(5):585\u201391.","journal-title":"Oncologist."},{"issue":"14","key":"2032_CR29","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow up of the multicohort single-arm phase II Check Mate 205 trial. J Clin Oncol. 2018;36(14):1428\u201339.","journal-title":"J Clin Oncol"},{"issue":"18","key":"2032_CR30","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","volume":"129","author":"C Herbaux","year":"2017","unstructured":"Herbaux C, Gauthier J, Brice P, et al. Efficacy\u00a0and\u00a0tolerability\u00a0of\u00a0nivolumab\u00a0after\u00a0allogeneic transplantation\u00a0for\u00a0relapsed\u00a0Hodgkinlymphoma. Blood. 2017;129(18):2471\u20138.","journal-title":"Blood"},{"key":"2032_CR31","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Geneva: World Health Organization; 2008.","edition":"4"},{"issue":"9323","key":"2032_CR32","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359(9323):2065\u201371.","journal-title":"Lancet."},{"issue":"3","key":"2032_CR33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00277-014-2215-9","volume":"94","author":"A Salihoglu","year":"2015","unstructured":"Salihoglu A, Elverdi T, Karadogan I, et al. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol. 2015;94(3):415\u201320.","journal-title":"Ann Hematol"},{"issue":"18","key":"2032_CR34","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30(18):2183\u20139.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2032_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/annonc\/mdw169","volume":"27","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Chihara D, Horowitz S, et al. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol. 2016;27(7):1317\u201323.","journal-title":"Ann Oncol"},{"issue":"6","key":"2032_CR36","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00262-015-1689-1","volume":"64","author":"J Martin-Liberal","year":"2015","unstructured":"Martin-Liberal J, Furness AJ, Joshi K, et al. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother. 2015;64(6):765\u20137.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2032_CR37","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","volume":"38","author":"J Hughes","year":"2015","unstructured":"Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015;38(4):e55\u20137.","journal-title":"Diabetes Care"},{"issue":"6","key":"2032_CR38","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/jdi.12531","volume":"7","author":"M Okamoto","year":"2016","unstructured":"Okamoto M, Okamoto M, Gotoh K, et al. Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig. 2016;7(6):915\u20138.","journal-title":"J Diabetes Investig."},{"issue":"2","key":"2032_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1620\/tjem.239.155","volume":"239","author":"Y Miyoshi","year":"2016","unstructured":"Miyoshi Y, Ogawa O, Oyama Y. Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes. Tohoku J Exp Med. 2016;239(2):155\u20138.","journal-title":"Tohoku J Exp Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-018-02032-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-018-02032-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-018-02032-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:58:44Z","timestamp":1659095924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-018-02032-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,9]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8,12]]}},"alternative-id":["2032"],"URL":"https:\/\/doi.org\/10.1007\/s12094-018-02032-4","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"type":"print","value":"1699-048X"},{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2019,2,9]]},"assertion":[{"value":"12 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work has no human or animal participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval (research involving human participants and\/or animals)"}},{"value":"There is no consent for this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}